Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 1966; 16(01/02): 302-310
DOI: 10.1055/s-0038-1655564
DOI: 10.1055/s-0038-1655564
Originalarbeiten — Original Articles — Travaux Originaux
Distribution, Half Life Time and Placental Transfer of the Protease Inhibitor Trasylol
This work was aided by a grant from the National Institute of Child Healt and Human Development HD 00270-05.
Further Information
Publication History
Publication Date:
26 June 2018 (online)
Summary
A method is described for an assay of Trasylol in the circulation. By this method it was found that Trasylol disappears rapidly from the circulation. The half life time of elimination is approximately 150 minutes. The placental barrier is not crossed by this substance.
*) Career Scientist of the Health Research Council of the City of New York under contract I 297.
**) NIH Research Trainee under contract 5-TI-HD-l 1-05.
***) Privatdozent für Pharmakologie, University of Göttingen.
-
References
- 1 Anderer F. A, Hornle S. Strukturuntersuchungen anKallikrein-Inaktivator aus Rinderlunge. I. Molekulargewicht, Endgruppenanalyse und Aminosäure-Zusammensetzung. Z. Naturforsch 20: 451 1965;
- 2 Astrup T. Lung tissue as a proteolytic inhibitor. Acta physiol. scand 26: 243 1952;
- 3 Auhagen J. Verteilung und Elimination von Trasylol bei der Maus. Dissertation. Düsseldorf 1964
- 4 Beck E, Schmutzler R, Duckert F. Inhibition of fibrinolysis and fibrinogenolysis in man: comparison of E-amino-caproic-acid and Kallikrein inhibitor. Thrombos. Diathes. hemorrh. (Stuttg.) 10: 106 1963;
- 5 Beller F. K. Treatment of coagulation disorders in pregnancy. Clin. Obstet. Gynec 7: 372 1964;
- 6 Beller F. K, Douglas G. W, Epstein M. D. The fibrinolytic system in the newborne. (Inpress.)
- 7 Johnson A. V. Tse. In: Tocantis, L. and Kazal, Blood coagulation, hemorrhage and thrombosis. Grune and Stratton; London, New York: 1965
- 8 Kaller H. Tierexperimentelle Untersuchungen über Wirkungsdauer und Elimination von Trasylol. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak 246: 92 1963;
- 9 Kraut H, Bhargava N, Schidtz F, Zimmermann H. Versuche zur Isolierung des Kallikrein -Inaktivators IV. Hoppe-Seylers Z. physiol. Chem 334: 230 1963;
- 10 Kraut H, Frey E. K, Werle E. Über die Inaktivierung des Kallikreins. Hoppe-Seylers Z. physiol. Chem 192: 1 1930;
- 11 Kunitz M, Northrop J. H. Isolation from beef pancreas of crystalline trypsinogen, trypsin, atrypsin inhibitor and an inhibitor-Trypsin. J. gen. Physiol 19: 991 1936;
- 12 Marx R, demente P, Werle E, Appel W. Zum Problem eines Antidots in der internen Thrombotherapie mit fibrinolytika. Blut 5: 367 1959;
- 13 Marx R. Wirkungsweise der Fibrinolytica und Antifibrinolytica. Thrombos. Diathes. hemorrh 7 (Suppl. 03) 27 1963;
- 14 Werle E, Trautschold J. Bestimmung des Kallikrein-Inaktivators. ,,Trasylol” im Blut und in Organen und seine Verteilung nach Injektionen. Münch, med. Wschr 103: 773 1961;